Work

Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC

Year: 2026
Type: article
Abstract: Cancer-associated fibroblasts (CAFs), as crucial stromal components in the tumor microenvironment, promote tumor progression and impair responses to immunotherapy. However, targeted therapies against CAFs remain limited in HPV-negative head and neck squamous cell carcinoma (HPV - HNSCC). Here, integrated analysis of single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing, ChIP sequencing, and spatial transcriptomic data identified a candidate epigenetic fibroblast target. We revealed that SET and MYND domain-containing 3 (SMYD3) played a critical role in the transformation of fibroblasts into myofibroblasts. It promoted collagen production to impair infiltration of CD8 + T cells and upregulated THBS2 in CAFs to induce M2‑like macrophage polarization. Functional studies confirmed that targeting SMYD3 not only improved the immune environment but also enhanced the efficacy of anti‑PD‑L1 therapy in vivo. Our findings established SMYD3 as a central mediator of CAF-dependent immune suppression and nominated its inhibition as a promising strategy to improve immunotherapy outcomes in HPV - HNSCC.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,090
Award: G214358020
OpenAlex ID: W7236257092
FWCI:
Cites: 45
Cited by:
Related to: 10